Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Borderline Personality Disorder Clinical Trials

A listing of Borderline Personality Disorder medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (27) clinical trials

fMRI in Impulsivity

This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.

Phase N/A

Guanfacine to Treat Borderline Personality Disorder

This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking ...

Phase N/A

Neural Correlates of Stress Hormones

The investigators have recently shown that hydrocortisone enhances rather than impairs memory retrieval in patients with posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD). In contrast, in healthy participants memory retrieval was impaired after hydrocortisone compared to placebo. The proposed studies aim to further investigate these findings and to ...

Phase N/A

Narrative Exposure Therapy in Women With Borderline Personality Disorder and Posttraumatic Stress Disorder

Narrative Exposure Therapy (NET) is an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversity. Patients with Borderline Personality Disorder (BPD) often suffer from a comorbid Posttraumatic Stress Disorder (PTSD) caused by multiple traumatic events. Therapeutic aims are the reduction of PTSD-Symptoms ...

Phase N/A

Evaluation of AIT Study

Specialized treatment of personality disorders (PD) in youth has been neglected for a long time, because these disorders were not diagnosed before the age of 18. Since 2013 the age threshold has been dropped in the Diagnostic and Statistical Manual (DSM)-5, and such change is also announced for the International ...

Phase N/A

Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD

Background: Borderline personality disorder (BPD) is a chronic and debilitating syndrome associated with considerable morbidity, mortality, and high rates of medical and psychiatric utilization services. The prevalence of BPD is around 1%-2% in general population. However, suicidality and self-injury are common, an estimated 69-80% of patients with BPD attempt suicide ...

Phase N/A

An 18-Month Psychotherapy of Borderline Personality Disorder

Patients with borderline personality disorder (BPD) will be provided with an empirically supported form of psychotherapy for BPD patients called transference-focused psychotherapy (TFP) and medication treatment, if indicated. The primary goal of the current study is to detect changes in psychological, psychosocial and work functioning over the course of 18-months ...

Phase N/A

DBT in Borderline Personality Disorder

Subjects will receive a 6-month course of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist.

Phase N/A

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance ...

Phase N/A

DBT and Escitalopram in Borderline Personality Disorder

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Phase N/A